KLK3 and Familial prostate cancer: The detection of GPC-1 in urine or blood, perhaps in combination with PSA and/or other biomarkers, may provide clinical benefit in terms of less invasive testing, earlier and more accurate detection of prostate cancer, and decrease the number of unnecessary biopsies.